Latham & Watkins advised Harmony Biosciences, while Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in the offering. Harmony Biosciences Holdings, Inc. (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Skadden is advising Otsuka, while Latham & Watkins is advising Jnana on the deal. Nutraceutical and pharmaceutical company Otsuka Holdings Co. Ltd., (Otsuka), announced the definitive...
You must be a Standard 1 Year member to access this content.
Cravath, Swaine & Moore represented Illumina, Inc. on the transaction, and Latham & Watkins represented GRAIL, LLC. GRAIL, Inc. (NASDAQ: GRAL, formerly GRAIL, LLC), a healthcare...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Boston Scientific Corporation in the transaction, and Wilson Sonsini Goodrich & Rosati represented Silk Road Medical. Boston Scientific Corporation (“Boston Scientific”) (NYSE:...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP represents Vistagen in the offering. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised PROCEPT BioRobotics, and Shearman & Sterling advised the underwriters. PROCEPT BioRobotics Corporation announced a follow-on offering of 5,085,494 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Goodwin Procter is serving as legal counsel to Korro Bio, Latham & Watkins is serving as Frequency Therapeutics’ legal counsel, and Davis Polk is serving as...
You must be a Standard 1 Year member to access this content.
Latham & Watkins Advises Guardant Health in Pricing of Upsized Public Offering of Common Stock. Guardant Health, Inc., a leading precision oncology company, has announced the pricing...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
You must be a Standard 1 Year member to access this content.
